About this Journal Submit a Manuscript Table of Contents
ISRN Urology
Volume 2012 (2012), Article ID 391705, 7 pages
http://dx.doi.org/10.5402/2012/391705
Clinical Study

Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center

1Département d’Oncologie Radiothérapie, CRLC Val d’Aurelle-Paul Lamarque, Montpellier 34298, France
2Département de Radio-Oncologie, Hôpital Maisonneuve-Rosemont, Montréal, QC, H1T 2M4, Canada
3Department of Urology, Clinique Beausoleil, Montpellier 34070, France

Received 4 December 2011; Accepted 3 January 2012

Academic Editor: M.-L. Hsieh

Copyright © 2012 Olivier Riou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Anscher, R. Clough, and R. Dodge, “Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years,” International Journal of Radiation Oncology Biology Physics, vol. 48, no. 2, pp. 369–375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Stephenson, P. T. Scardino, M. W. Kattan et al., “Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 2035–2041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. A. K. Leventis, S. F. Shariat, M. W. Kattan, E. B. Butler, T. M. Wheeler, and K. M. Slawin, “Prediction of response to salvage radiation therapy in patients with prostrate cancer recurrence after radical prostatectomy,” Journal of Clinical Oncology, vol. 219, no. 4, pp. 1030–1039, 2001. View at Scopus
  4. A. K. Leventis, S. F. Shariat, and K. M. Slawin, “Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings,” Radiology, vol. 219, no. 2, pp. 432–439, 2001. View at Scopus
  5. J. Y. Wo, M. H. Chen, P. L. Nguyen et al., “Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 6000–6005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy,” Journal of the American Medical Association, vol. 294, no. 4, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. V. D'Amico, J. Moul, P. R. Carroll et al., “Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy,” Journal of Urology, vol. 172, no. 5, pp. S42–S47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. V. D'Amico, J. W. Moul, P. R. Carroll, L. Sun, D. Lubeck, and M. H. Chen, “Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy,” Journal of the National Cancer Institute, vol. 95, no. 18, pp. 1376–1383, 2003. View at Scopus
  9. S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1765–1771, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. V. D'Amico, M. H. Chen, K. A. Roehl, and W. J. Catalona, “Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy,” The New England Journal of Medicine, vol. 351, no. 2, pp. 125–135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Bottke, T. M. de Reijke, D. Bartkowiak, and T. Wiegel, “Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer,” European Journal of Cancer, vol. 45, no. 1, pp. 148–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. T. K. Choueiri, M. H. Chen, A. V. D'Amico et al., “Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death,” Cancer, vol. 116, no. 8, pp. 1887–1892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Feng, A. L. Hanlon, T. M. Pisansky et al., “Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 68, no. 5, pp. 1417–1423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Pearse, R. Choo, C. Danjoux et al., “Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 792–798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Pasquier and C. Ballereau, “Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 4, pp. 972–979, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Bolla, H. Van Poppel, L. Collette et al., “Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911),” The Lancet, vol. 366, no. 9485, pp. 572–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Wiegel, D. Bottke, U. Steiner et al., “Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 2924–2930, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. I. M. Thompson, C. M. Tangen, J. Paradelo et al., “Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial,” Journal of the American Medical Association, vol. 296, no. 19, pp. 2329–2335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. G. De Meerleer, V. Fonteyne, S. Meersschout et al., “Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy,” Radiotherapy and Oncology, vol. 89, no. 2, pp. 205–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Poortmans, A. Bossi, K. Vandeputte et al., “Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group,” Radiotherapy and Oncology, vol. 84, no. 2, pp. 121–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. A. Sidhom, A. B. Kneebone, M. Lehman et al., “Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group,” Radiotherapy and Oncology, vol. 88, no. 1, pp. 10–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Michalski, C. Lawton, I. El Naga et al., “Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 2, pp. 361–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. K. Pietrow, D. J. Parekh, J. A. Smith, Y. U. Shyr, and M. S. Cookson, “Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence,” Journal of Urology, vol. 166, no. 6, pp. 2286–2290, 2001. View at Scopus
  24. J. Camilleri-Brennan and R. J. C. Steele, “The impact of recurrent rectal cancer on quality of life,” European Journal of Surgical Oncology, vol. 27, no. 4, pp. 349–353, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. A. B. Jani and J. Kao, “Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis,” Cancer, vol. 103, no. 9, pp. 1833–1842, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. I. M. Thompson, C. M. Tangen, J. Paradelo et al., “Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial,” Journal of Urology, vol. 181, no. 3, pp. 956–962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. I. M. Thompson, C. M. Tangen, and E. A. Klein, “Is there a standard of care for pathologic stage T3 prostate cancer?” Journal of Clinical Oncology, vol. 27, no. 18, pp. 2898–2899, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Bolla, H. Van Poppel, and L. Collette, “Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression,” Cancer Radiotherapie, vol. 11, no. 6-7, pp. 363–369, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Parker, N. Clarke, J. Logue, et al., “RADICALS (radiotherapy and androgen deprivation in combination after local surgery),” Clinical Oncology, vol. 19, no. 3, pp. 167–171, 2007.
  30. C. Catton, “The role of radiation therapy in prostate cancer after radical prostatectomy: when and why?” Current Opinion in Supportive and Palliative Care, vol. 4, no. 3, pp. 135–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Richaud, P. Sargos, B. Henriques de Figueiredo et al., “Postoperative radiotherapy of prostate cancer,” Cancer Radiotherapie, vol. 14, no. 6-7, pp. 500–503, 2010. View at Scopus
  32. C. Parker, C. Catton, and M. R. Sydes, “Early salvage radiotherapy after radical prostatectomy,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 45–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Heidenreich, G. Aus, M. Bolla et al., “EAU guidelines on prostate cancer,” European Urology, vol. 53, no. 1, pp. 68–80, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. L. Grubb and A. S. Kibel, “High-risk localized prostate cancer: role of radical prostatectomy,” Current Opinion in Urology, vol. 20, no. 3, pp. 204–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Van Poppel and S. Joniau, “An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer,” European Urology, vol. 53, no. 2, pp. 253–259, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. G. H. M. Cremers, E. N. J. T. van Lin, W. L. J. Gerrits et al., “Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy,” Radiotherapy and Oncology, vol. 97, no. 3, pp. 467–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Menkarios, D. Azria, B. Laliberté et al., “Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans,” Radiation Oncology, vol. 2, no. 1, article 41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. C. X. Yu, C. J. Amies, and M. Svatos, “Planning and delivery of intensity-modulated radiation therapy,” Medical Physics, vol. 35, no. 12, pp. 5233–5241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Guerrero, X. A. Li, L. Ma, J. Linder, C. Deyoung, and B. Erickson, “Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations,” International Journal of Radiation Oncology Biology Physics, vol. 62, no. 3, pp. 933–939, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Fenoglietto, B. Laliberte, A. Allaw et al., “Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk,” Radiotherapy and Oncology, vol. 88, no. 1, pp. 77–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Azria, N. Aillères, C. Llacer Moscardo, M. H. Hay, J. B. Dubois, and P. Fenoglietto, “Conformal intensity modulated radiation therapy for localized prostate cancer: toward a new standard,” Cancer Radiotherapie, vol. 13, no. 5, pp. 409–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Staffurth, “A review of the clinical evidence for intensity-modulated radiotherapy,” Clinical Oncology, vol. 22, no. 8, pp. 643–657, 2010.
  43. A. A. Aizer, J. B. Yu, J. W. Colberg, A. M. McKeon, R. H. Decker, and R. E. Peschel, “Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Al-Mamgani, W. D. Heemsbergen, S. T. H. Peeters, and J. V. Lebesque, “Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 73, no. 3, pp. 685–691, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. J. Chen, E. Weltman, R. M. Hanriot et al., “Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?” Radiation Oncology, vol. 2, no. 1, article 6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. G. O. De Meerleer, V. H. Fonteyne, L. Vakaet et al., “Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control,” Radiotherapy and Oncology, vol. 82, no. 2, pp. 160–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Digesú, S. Cilla, A. De Gaetano et al., “Postoperative intensity modulated radiation therapy in high risk prostate cancer: a dosimetric comparison,” Medical Dosimetry, vol. 36, no. 3, pp. 231–239, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. B. F. Koontz, S. Das, K. Temple et al., “Dosimetric and radiobiologic comparison of 3D conformal versus intensity modulated planning techniques for prostate bed radiotherapy,” Medical Dosimetry, vol. 34, no. 3, pp. 256–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Ost, B. De Troyer, V. Fonteyne, W. Oosterlinck, and G. De Meerleer, “A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 80, no. 5, pp. 1316–1322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Ost, V. Fonteyne, G. Villeirs, N. Lumen, W. Oosterlinck, and G. De Meerleer, “Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients,” European Urology, vol. 56, no. 4, pp. 669–677, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. M. D. Bastasch, B. S. Teh, W. Y. Mai et al., “Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 1, pp. 101–106, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Alongi, C. Fiorino, C. Cozzarini et al., “IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 207–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. S. K. Nath, A. P. Sandhu, B. S. Rose et al., “Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 2, pp. 435–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Sandhu, R. Sethi, R. Rice et al., “Prostate bed localization with image-guided approach using on-board imaging: reporting acute toxicity and implications for radiation therapy planning following prostatectomy,” Radiotherapy and Oncology, vol. 88, no. 1, pp. 20–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. B. S. Teh, W. Y. Mai, M. E. Augspurger et al., “Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 49, no. 2, pp. 465–472, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. B. W. Corn, K. Winter, and M. V. Pilepich, “Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31 Radiation Therapy Oncology Group,” Urology, vol. 54, no. 3, pp. 495–502, 1999.
  57. Y. Neuzillet, S. Négrier, K. Fizazi et al., “The French clinical trials ongoing (GETUG and AFU) on urothelial carcinomas, kidney and prostate cancers,” Progrès en Urologie, vol. 20, supplement 1, pp. S84–S89, 2010. View at Publisher · View at Google Scholar · View at Scopus